Ossium Health Names Edwin Horwitz Medical Affairs Director

The bioengineering company appointed a veteran pediatric hematologist and transplant physician to lead its Medical Affairs organization.

Updated on Nov. 18, 2026 in People

Isometric editorial illustration of a cryogenic storage canister with frosted vapor beside translucent cell clusters on a laboratory bench, in slate, cream, and oxblood.
Ossium Health named Edwin Horwitz, MD, PhD, its Executive Director of Medical Affairs, tapping a veteran pediatric transplant physician to lead its donor-derived bone marrow bank work. AI Illustration. Upload story photo >

Ossium Health, which built the world's first bank of organ donor-derived bone marrow, appointed Edwin Horwitz, MD, PhD, as Executive Director of Medical Affairs. Ossium announced the appointment on November 18, 2026, through a GlobeNewswire press release.

Why it matters

Horwitz will lead Ossium's Medical Affairs organization and work with transplant centers as they bring Ossium's bone marrow bank into their practice. His clinical and research background gives transplant physicians a new point of contact for an option in their patients' care.

Horwitz's appointment is cited as building on more than 30 years of transplant and cell therapy experience, and Ossium, founded in 2016, operates a manufacturing facility registered with the FDA and a laboratory certified under the Clinical Laboratory Improvement Amendments. The release does not disclose compensation, headcount changes or the size of the Medical Affairs team.

The players

Ossium Health

Ossium Health is a bioengineering company founded in 2016 that built the world's first bank of organ donor-derived bone marrow.

Edwin Horwitz, MD, PhD

Edwin Horwitz is a pediatric hematologist, oncologist and blood and marrow transplant physician who formerly led cellular therapy work at Emory University School of Medicine.

The details

Horwitz is a pediatric hematologist, oncologist and blood and marrow transplant physician who most recently was Marcus Professor of Cellular Therapies at Emory University School of Medicine and Children's Healthcare of Atlanta. He previously led early clinical studies of bone marrow-derived mesenchymal cell therapy for children with osteogenesis imperfecta and has served as sponsor or principal investigator on multiple FDA investigational new drug applications.

Timeline

  1. 2010 to 2012: Horwitz served as President of the International Society for Cell & Gene Therapy.

  2. 2016: Ossium Health was founded.

  3. November 18, 2026: Ossium announced Horwitz's appointment as Executive Director of Medical Affairs.

People

The move follows a pattern in which bioengineering companies hire physicians with academic transplant-center experience to bridge laboratory manufacturing and clinical adoption. Horwitz's background at Emory and Children's Healthcare of Atlanta positions Ossium to work directly with the centers that would use its donor-derived marrow.

Transplant physicians gain a new option for sourcing donor-derived bone marrow for their patients, though the release does not specify availability or eligibility. Patients and families are not directly affected by this personnel change in the near term.

The takeaway

Leadership changes at specialized biotech firms can signal a shift from manufacturing toward clinical adoption. Transplant teams evaluating new marrow sources should watch for the company's medical affairs engagement with their centers.

Further reading

Explore more business people coverage from San Francisco.

More information

Visit the Ossium Health company website for information about its bone marrow bank.

Source note: This article includes information reported by The Manila times.